Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:DOW
NYSE:DOWChemicals

Is It Too Late To Consider Dow (DOW) After Its Recent Share Price Surge?

If you are wondering whether Dow's recent run makes it overpriced or still attractive, its current valuation story is worth a closer look before you decide what to do next. The share price sits at US$40.82, with returns of 11.4% over 7 days, 36.0% over 30 days, 68.2% year to date and 26.8% over the past year. This compares with weaker 3 year and 5 year returns of 11.0% and 17.0% declines. These moves have come as Dow remains in focus for investors following ongoing attention on the broader...
NasdaqGS:PCAR
NasdaqGS:PCARMachinery

A Look At PACCAR (PCAR) Valuation After Recent Share Price Weakness

How PACCAR Stock Has Been Trading Recently PACCAR (PCAR) has been relatively steady in recent months, with a last close of US$112.75. The stock shows a 1 day return of 2.24%, a 7 day gain of 1.34%, and a month decline of 9.50%. Over the past 3 months, PACCAR has a 0.86% total return, while year to date performance stands at 1.07%. Longer term, the stock shows a 19.33% 1 year total return and gains over 3 and 5 years. See our latest analysis for PACCAR. The recent 9.5% 1 month share price...
NYSE:ARES
NYSE:ARESCapital Markets

A Look At Ares Management (ARES) Valuation After Redemptions Are Capped At Its Strategic Income Fund

Ares Management (ARES) is back in focus after its Ares Strategic Income Fund capped quarterly redemptions at 5%, following withdrawal requests of 11.6% that echoed wider pressures across the private credit market. See our latest analysis for Ares Management. The recent redemption cap comes after a sharp 37.0% 90 day share price return decline and a 36.1% year to date share price return decline. However, the 5 year total shareholder return of 114.98% remains firmly positive, suggesting...
XTRA:GMM
XTRA:GMMAuto Components

Grammer (XTRA:GMM) Margin Repair To €16.7m TTM Profit Tests Cautious Narratives

Grammer (XTRA:GMM) has just reported its FY 2025 third quarter, with revenue of €433.2 million and EPS of €0.47. Trailing twelve month figures show revenue of about €1.8 billion and EPS of €1.12, reflecting the impact of a one off loss of €36.5 million from discontinued operations over the period. Over recent quarters, revenue has ranged from €487.4 million in Q1 2025 to €500.5 million in Q2 2024. Over the same timeframe, EPS has moved between a loss of €3.96 in Q3 2024 and a gain of €0.60 in...
XTRA:WUW
XTRA:WUWInsurance

Wüstenrot & Württembergische (XTRA:WUW) Profit Rebound Tests Long Term Earnings Decline Narrative

Wüstenrot & Württembergische (XTRA:WUW) has put solid numbers on the table, with first half FY 2025 revenue of €2.9b and net income of €90m, translating to EPS of €0.96 and trailing twelve month EPS of €1.48 on €5.6b of revenue. Over the past three reported halves, revenue has moved from €2.65b in H1 2024 to €2.74b in H2 2024 and then to €2.9b in H1 2025. EPS shifted from a loss of €0.16 in H1 2024 to €0.52 in H2 2024 and €0.96 in H1 2025, setting up a story where traders will focus on how...
SWX:GAM
SWX:GAMCapital Markets

GAM Holding (SWX:GAM) Losses Of CHF 40.7m Test Bullish Profitability Narratives

GAM Holding (SWX:GAM) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 25.7 million and basic EPS of CHF 0.038 loss per share, while trailing 12 month figures to the same point show revenue of CHF 62.5 million and a basic EPS loss of CHF 0.100897. Over the past three reported halves, revenue has moved from CHF 43.9 million in 1H 2024 to CHF 37.7 million in 2H 2024 and then to CHF 25.7 million in 1H 2025, alongside basic EPS losses of CHF 0.248253, CHF 0.08653 and...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story

AstraZeneca reported that its antibody drug tozorakimab succeeded in two Phase 3 trials in chronic obstructive pulmonary disease (COPD), targeting a broad COPD patient population. The news introduces a new competitor to Regeneron Pharmaceuticals and Sanofi's Dupixent in COPD, an area where similar biologics had previously seen COPD trial setbacks. This development could affect how investors think about the size of the COPD biologics market and the longer term revenue potential tied to...
ENXTPA:FR
ENXTPA:FRAuto Components

Valeo’s US Plant Deepens Role In GM Software Defined Vehicles

Valeo (ENXTPA:FR) is investing $225 million in a new manufacturing facility in Texas. The plant will produce central compute units for General Motors' software-defined vehicles. The project supports one of the largest orders in Valeo's history and expands its US footprint. For investors watching the auto technology space, this move places Valeo more firmly among the suppliers building the electronics behind software-defined vehicles. The Texas facility connects directly to Valeo's existing...
NasdaqGM:MDB
NasdaqGM:MDBIT

Is It Time To Revisit MongoDB (MDB) After Its Recent Share Price Slide?

If you are wondering whether MongoDB's current share price reflects its true worth, it helps to break the story into what the market has done, what has been happening around the company, and how that ties back to valuation. The stock closed at US$235.51, with a 9.8% decline over the last 7 days, a 25.2% decline over the last 30 days, and a 41.1% decline year to date. This comes even while the 1 year return sits at 32.3% and the 3 year return at 1.0%, compared to a 5 year return of an 18.9%...
NasdaqGS:LAUR
NasdaqGS:LAURConsumer Services

Earnings Beat, Buybacks and Soft Guidance Might Change The Case For Investing In Laureate Education (LAUR)

Laureate Education recently reported a strong quarter, with revenue and EPS ahead of analyst expectations, continued investment in new campuses and digital and AI capabilities, and over US$200 million returned to shareholders via share repurchases, while CFO Richard M. Buskirk sold 61,803 shares but retained the majority of his stake. Despite delivering the fastest revenue growth among peers and emphasizing ongoing business momentum, Laureate Education issued the weakest full-year guidance...
NYSE:BLX
NYSE:BLXDiversified Financial

A Look At Bladex (BLX) Valuation After Its 2030 Investor Day Trade Banking Plan

Investor Day plan and proposed rebrand put Bladex in focus Banco Latinoamericano de Comercio Exterior S. A (BLX) has moved into the spotlight after its 2026 Investor Day, where management outlined a 2030 plan to build a more transactional regional trade banking platform. The bank also plans to ask shareholders at the April 21, 2026 AGM to approve a name change to Bladex Inc. It will gradually roll out transactional services aimed at growing deposits, payments activity, and fee income. See our...
TSX:DML
TSX:DMLOil and Gas

Did Denison’s Phoenix Mine Construction Decision Just Shift Denison Mines’ (TSX:DML) Investment Narrative?

Earlier in March 2026, Denison Mines announced a final investment decision to construct the Phoenix in-situ recovery uranium mine at its Wheeler River project, after receiving key Canadian Nuclear Safety Commission approvals and advancing engineering work. This move effectively transitions Denison from planning into execution on a major uranium development, reshaping expectations around its future production profile. With this step toward building the Phoenix in-situ recovery mine, we'll...
NYSE:CDRE
NYSE:CDREAerospace & Defense

Cadre Holdings Buys Alien Gear Holsters What It Means For Valuation

Cadre Holdings (NYSE:CDRE) has agreed to acquire Alien Gear Holsters through a court supervised bankruptcy auction. The deal remains subject to court and regulatory approvals before closing. Alien Gear Holsters is known for its holster products and direct to consumer sales channels. For investors watching NYSE:CDRE, the move adds a well known holster brand to Cadre Holdings' existing portfolio of safety and protection equipment. Alien Gear Holsters brings an established consumer following...
BME:CEV
BME:CEVReal Estate

CEV (BME:CEV) Margin Compression In H1 2025 Challenges Bullish Narratives

Compañía Española de Viviendas en Alquiler (BME:CEV) has put fresh numbers on the table for H1 2025, reporting total revenue of €18.9 million and basic EPS of €0.42, with trailing 12 month revenue at €46.4 million and EPS at €0.94. Over the past year and a half, revenue has moved from €10.1 million in H1 2024 to €27.5 million in H2 2024 and now €18.9 million in H1 2025, while basic EPS tracked at €0.50, €0.52 and €0.42 over the same half yearly periods. This sets the backdrop for how you read...
NasdaqGS:CASY
NasdaqGS:CASYConsumer Retailing

Why Casey's General Stores (CASY) Is Up 8.3% After Highlighting Fuel Margins, Loyalty Growth, Expansion Plans

Casey’s General Stores recently highlighted strong third-quarter performance, with wider fuel margins, higher inside same-store sales supported by its 10-million‑plus Rewards members, ongoing store expansion plans, and a long history of dividend increases. An interesting angle is how this combination of fuel profitability, loyalty-driven in-store growth, and expansion ambitions is drawing fresh attention from Wall Street analysts assessing the company’s longer-term strengths and risks. Next,...
NYSE:RCUS
NYSE:RCUSBiotechs

Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound

Stock performance snapshot Arcus Biosciences (RCUS) has drawn investor attention after recent trading left the stock near US$20.28, with returns showing mixed moves over the past week, month and past 3 months. See our latest analysis for Arcus Biosciences. While the recent 1 day share price return of a 4.38% decline and 7 day share price return of a 6.28% decline show pressure at around US$20.28, the 1 year total shareholder return of 148.23% points to strong longer term momentum despite...
NasdaqCM:HYNE
NasdaqCM:HYNEBanks

Hoyne Bancorp (HYNE) Net Interest Margin Tops 3% Challenging Cautious Narratives

Hoyne Bancorp (HYNE) has just posted its FY 2025 figures with third quarter revenue at roughly US$3.5 million and net income at about US$0.1 million, set against trailing 12 month revenue of around US$13.2 million and a loss of roughly US$0.4 million. Over the last few reported periods, the bank has seen revenue move from about US$2.5 million in Q3 2024 to roughly US$3.5 million in Q3 2025, while TTM revenue shifted from around US$10.3 million to about US$13.2 million. This provides a clearer...
NasdaqGM:APPN
NasdaqGM:APPNSoftware

Assessing Appian (APPN) Valuation After Prolonged Share Price Weakness

Recent share performance and business snapshot Appian (APPN) has drawn investor attention after a period of weaker share performance. The stock has shown negative returns over the past week, month and past 3 months, and a 1 year total return decline of 21%. The company runs The Appian Platform, an automation and low code software offering used across industries such as financial services, government, life sciences and insurance. Its operations are supported by cloud subscriptions, licenses...
NYSE:ROK
NYSE:ROKElectrical

Is It Too Late To Consider Rockwell Automation (ROK) After Its Recent Share Price Pullback?

If you are wondering whether Rockwell Automation at around US$351.50 is priced for opportunity or already fully valued, the starting point is understanding what the current market price is actually reflecting. The stock has seen mixed recent returns, with a 1% decline over the last 7 days and a 12.6% decline over the last 30 days, while still showing 38.0% over 1 year, 26.1% over 3 years and 45.2% over 5 years. Recent coverage has focused on Rockwell Automation's role in industrial...
CPSE:NOVO B
CPSE:NOVO BPharmaceuticals

Novo Nordisk’s Weekly Awiqli Insulin Approval Meets Depressed Share Price

Novo Nordisk has received FDA approval for Awiqli®, the first once weekly basal insulin for adults with type 2 diabetes. The product introduces a new treatment option that reduces injection frequency compared with daily basal insulin regimens. This approval adds a new diabetes therapy alongside existing products and may influence how investors think about CPSE:NOVO B. Novo Nordisk, trading at DKK228.5 per share, has recently seen share price returns of 18.2% over five years, but a 54.5%...
NYSE:SNAP
NYSE:SNAPInteractive Media and Services

Is Growing Child‑Safety Scrutiny For Snap (SNAP) Rewriting Its Core Product And Profitability Model?

In recent weeks, Snap has been hit with a series of legal and regulatory actions, including a US federal lawsuit alleging platform design enabled the exploitation of a minor and an EU investigation into potential failures to protect children under the Digital Services Act. These cases put Snap’s child-safety practices and content controls under intense scrutiny, raising questions about how future compliance obligations could affect its product design and operating model. We’ll now examine...